ChanTest Corporation First To Offer New High Throughput Electrophysiology Platform Validated for Both VGICs and LGICs
Published: Apr 06, 2011
CLEVELAND--(BUSINESS WIRE)--Beginning next month, ChanTest Corporation will offer the highest throughput electrophysiology platform on the market validated for both voltage-gated (VGIC) and rapidly desensitizing ligand-gated ion channels (LGICs). LGICs typically are not well suited for automated platform assays but by using the first IonWorks Barracuda™ System ever sold by Molecular Devices, ChanTest adds even greater capacity to its state of the art screening operation. A unique, flow-through well design and rapid solution exchange rate allows for accurate automated LGIC screening.